Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPL026 intravenous DMT in healthy adults and adults with major depressive disorder
ISRCTN63465876Phase 2Completed
- Sponsor
- Small Pharma
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of SPL026 in major depressive disorder (MDD), sponsored by Small Pharma. Started Dec 2020; status: completed.
02
Drugs
SPL026
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN63465876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN63465876.